The global transdermal drug delivery Systems market was valued at USD 6,225.2 Million in 2020 and is expected to reach USD 8,654.9 Million by the year 2030, at a CAGR of 4.1%. Transdermal drug delivery is a method of administering medications through the skin, in which the systemic circulation gradually absorbs medicines. Depending on the type of distribution system, the market has become an active and passive distribution system. The passive delivery system is expected to retain the largest share of the global market throughout the analysis period, due to the increased prevalence of chronic conditions such as hypertension and the increasing adoption of these devices. The active procurement system is expected to experience faster growth in market demand for transdermal drug delivery systems, mainly driven by product launches.
Transdermal drug delivery systems generally consist of five key components, namely the drug, the polymer matrix, the permeation enhancers, the adhesives, and the support layers. Factors that directly affect the quality, permeability, and efficacy of transdermal drug delivery include morphology and physiology of the skin and the combination of the skin, penetrant, and delivery system. The increasing inclination of patients, as well as physicians, to deliver painless medications, is expected to contribute significantly to market growth, which is expected to stimulate market demand over the forecast period. Transdermal patches provide better control of toxicity levels because they can be easily removed if the medicine is tested for higher toxicity. This method makes it possible to monitor and estimate the permeation of the drug more effectively. This method facilitates the maintenance of a constant serum level of the drug. Given these factors, the rate of adoption of products in the global market for transdermal drug delivery is high.
The transdermal drug delivery system is one of the fastest-growing segments of the drug supply industry because it is the most convenient drug delivery system. The drivers of the transdermal drug supply market are the rapid technological advances in transdermal drug delivery systems and the increasing adoption of third-generation supply systems, the growth of the geriatric population, and the increased prevalence of chronic diseases in developing countries.
Salient Trends of the Transdermal Drug Delivery System Market
- Increasing disposable income and continuous improvement in health care infrastructure in emerging economies are among the most striking factors that should create many growth opportunities for the transdermal drug delivery market.
- In addition, the aging of the population and the increasing adoption of new drug delivery system technologies are also supporting the growth of the market for transdermal drug delivery systems.
- The increasing patient preference for pain-free drug delivery has resulted in a significant increase in the rate of adoption of skin adhesive patches that administer medications. This will in turn anticipate the market for transdermal drug delivery with high growth potential.
- In addition, the incorporation of transdermal systems will promote patient self-sufficiency by significantly reducing the frequency of hospital visits and the cumulative costs of treatment.
- The market has witnessed the development of new adhesives, molecular uptake activators and penetration enhancers that are expected to improve skin permeability, which has broadened the range of medications that should be to be delivered transdermally.
- This drug delivery system offers several benefits, such as reduced dosing frequency, improved bioavailability, reduced adverse events and interruption of medicine’s entry at any time by removing the patch.
- However, the disadvantages of administration systems such as irritation and edema, the natural restriction of the entry of the drug imposed by the permeability of the skin and the adhesion of the system to different types of skin are factors which should prevent the growth of the market.
Companies considered and profiled in this market study
Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
- As of 2019, Patches is the leading product segment of the global Transdermal Drug Delivery System Patches segment is expected to register highest CAGR among Transdermal Drug Delivery System at 4.9%.
- Semisolid formulations segment was valued at 2.2 billion in 2019 and is expected to grow at the rate of 4.3%. The growth of the geriatric population in developing countries is the primary factor contributing to the market growth of this product segment.
- The market for pain management of applications type segment is expected to reach USD 2.6 billion by year 2026, growing at a CAGR of 4.4% during the forecast period.
- The increasing patient preference for pain-free drug delivery has resulted in a significant increase in the rate of adoption of skin adhesive patches that administer medications. This will in turn drive the market growth.
- Hormonal market is expected to cross USD 1.8 billion by the end of forecase period owing to need of the most convenient drug delivery system for quick results.
- Central Nervous System disorders market some decline in growth and will have third largest CAGR of around 4.2% cross approximately USD 2.1 billion by the end of 2026.
- Asia Pacific is expected to grow with the highest CAGR of 5.5% in the coming years, owing to an increase in the patient pool and high adoption of advanced technologies by the healthcare professionals is expected to show lucrative growth.
- Additionally, the growth of the geriatric population and the increased prevalence of chronic diseases in developing economies like India, China, and Japan is expected to further drive the market growth in Asia Pacific region during the forecast period 2019-26.
- North America will show the second largest CAGR of 4.3% and will reach market share of around 3.4 billion in the forecast period of 2019-26. The increasing adoption of new drug delivery system technologies is one of the major reasons behind the growth in the area.
Key Coverage of the Report
- Region and country-wise assessment from the period 2019-2030. For the study, 2019-2030 has been utilized as historical data, 2019 as the base year, and 2019-2030, has been derived as forecasts
- Regional Competitors clinical pipeline analysis
- Demand and Supply GAP Analysis
- Market share analysis of the key industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 6 years of all the mentioned segments, and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
Segments covered in the report
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, Reports and Data have segmented the Transdermal Drug Delivery System market on the basis of type, technology type, applications type, end use, and region:
Type (Revenue, USD Million; 2019–2030)
- Semisolid formulations
Technology Type (Revenue, USD Million; 2019–2030)
- Electric Current
- Mechanical Arrays
- Radio Frequency
Applications Type (Revenue, USD Million; 2019–2030)
- Pain Management
- Central Nervous System Disorders
- Hormonal Applications
- Cardiovascular Diseases
End Use (Revenue, USD Million; 2019–2030)
Regional Outlook (Revenue in USD Million; 2019–2030)
- North America
- Rest of the Europe
- Asia Pacific
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America